Basic & Clinical Medicine ›› 2024, Vol. 44 ›› Issue (3): 379-383.doi: 10.16352/j.issn.1001-6325.2024.03.0379

• Clinical Sciences • Previous Articles     Next Articles

Intensive phototherapy don't affect cellular immune function and short-term reactions after discharge in neonatal hyperbilirubinemia

LIU Zhen1, WANG Dalian1, ZHANG Jie2, ZHANG Qixing1, WANG Fei1*   

  1. 1. Department of Pediatrics; 2. Department of Clinical Laboratory, Shanghai Fifth People′s Hospital, Fudan University, Shanghai 200240, China
  • Received:2023-10-25 Revised:2024-01-04 Online:2024-03-05 Published:2024-02-22
  • Contact: *:wangfei0126@126.com

Abstract: Objective To investigate the effect of intensive phototherapy for neonatal hyperbilirubinemia on cellular immune function and short-term immune-related adverse effects. Methods Totally 180 infants with hyperbilirubinemia were treated with different light intensity, the efficacy, cellular immune function and immune adverse effects were followed up for six months after discharge. Results After phototherapy, serum interleukin-6 (IL-6) in both groups were decreased and CD4+ (%) and CD4+/CD8+ were increased than that before phototherapy. The decrease rate of total bilirubin in the intensive phototherapy group was significantly faster than that in the conventional phototherapy group, at the same time, the total duration of phototherapy and hospital stay were significantly shorter than that in the conventional phototherapy group (P<0.05). No statistical significance in the incidence of diarrhea, rash, fever and hypo-calcemia during hospitalization and no immune-related adverse effects in 6 months after discharge were recorded. Conclusions Compared with conventional phototherapy, intensive phototherapy reduces serum bilirubin level more quickly and shorten the duration of phototherapy and hospital stay. No common adverse effects nor immune-related adverse effects are recorded during hospitalization and the period of six months after discharge.

Key words: hyperbilirubinemia, intensive phototherapy, neonate, cellular immunity, adverse reaction

CLC Number: